Arizona State Retirement System Sells 71 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS)

Arizona State Retirement System decreased its position in Krystal Biotech, Inc. (NASDAQ:KRYS) by 1.1% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 6,171 shares of the company’s stock after selling 71 shares during the quarter. Arizona State Retirement System’s holdings in Krystal Biotech were worth $1,113,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently bought and sold shares of the company. Fifth Third Bancorp lifted its position in Krystal Biotech by 159.1% in the first quarter. Fifth Third Bancorp now owns 171 shares of the company’s stock valued at $31,000 after purchasing an additional 105 shares during the last quarter. GF Fund Management CO. LTD. bought a new position in shares of Krystal Biotech during the fourth quarter valued at approximately $95,000. Covestor Ltd raised its holdings in shares of Krystal Biotech by 972.7% during the fourth quarter. Covestor Ltd now owns 708 shares of the company’s stock valued at $111,000 after acquiring an additional 642 shares in the last quarter. GAMMA Investing LLC raised its holdings in shares of Krystal Biotech by 179.3% during the first quarter. GAMMA Investing LLC now owns 673 shares of the company’s stock valued at $121,000 after acquiring an additional 432 shares in the last quarter. Finally, Elevation Point Wealth Partners LLC purchased a new stake in Krystal Biotech in the first quarter worth $223,000. Institutional investors own 86.29% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on KRYS shares. HC Wainwright reissued a “buy” rating and issued a $240.00 target price on shares of Krystal Biotech in a research note on Tuesday, June 24th. Citigroup restated a “neutral” rating and issued a $176.00 target price (up previously from $155.00) on shares of Krystal Biotech in a report on Wednesday, July 9th. Guggenheim lowered their price target on Krystal Biotech from $195.00 to $189.00 and set a “buy” rating on the stock in a report on Wednesday, May 7th. Finally, Chardan Capital reissued a “buy” rating and issued a $219.00 target price on shares of Krystal Biotech in a report on Wednesday, May 7th. One analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $213.75.

Krystal Biotech Stock Down 1.8%

Shares of KRYS opened at $147.49 on Friday. Krystal Biotech, Inc. has a 52-week low of $122.80 and a 52-week high of $219.34. The firm’s fifty day moving average is $136.57 and its two-hundred day moving average is $155.93. The stock has a market cap of $4.26 billion, a PE ratio of 35.45 and a beta of 0.67.

Krystal Biotech (NASDAQ:KRYS) last issued its earnings results on Tuesday, May 6th. The company reported $1.20 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.38 by ($0.18). The company had revenue of $88.18 million during the quarter, compared to analyst estimates of $98.66 million. Krystal Biotech had a return on equity of 14.64% and a net margin of 37.17%. As a group, research analysts anticipate that Krystal Biotech, Inc. will post 6.14 earnings per share for the current year.

Insider Buying and Selling at Krystal Biotech

In other Krystal Biotech news, insider Suma Krishnan sold 1,389 shares of Krystal Biotech stock in a transaction that occurred on Wednesday, July 16th. The stock was sold at an average price of $150.00, for a total transaction of $208,350.00. Following the transaction, the insider owned 1,508,056 shares of the company’s stock, valued at $226,208,400. The trade was a 0.09% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Over the last quarter, insiders sold 49,800 shares of company stock worth $7,487,943. 13.70% of the stock is currently owned by company insiders.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).